More tools:Markets·Screener·Research Chat

Regeneron Pharmaceuticals Inc (REGN) Financial Statements

Regeneron Pharmaceuticals Inc
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6PX49
XNAS · usd
656.12▼ 6.97 (-1.05%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$14.9B
Net Income (TTM)$4.4B
EBITDA
Diluted EPS (TTM)
EBITDA Margin27.9%
Net Debt
Trading Information
Previous Close663.09
Day's Range653.31 – 663.10
52-Week Range541.00 – 821.11
Volume468.1K
Avg Volume971.6K
Share Statistics
Shares Outstanding104.8M
Employees15.4K
ExchangeXNAS
Listed1991-04-02

Key questions about Regeneron Pharmaceuticals Inc (REGN)

What is Regeneron Pharmaceuticals Inc's Market Cap?
Regeneron Pharmaceuticals Inc's Market Cap is $68.8B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Enterprise Value?
Regeneron Pharmaceuticals Inc's Enterprise Value is $69.5B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Trailing P/E?
Regeneron Pharmaceuticals Inc's Trailing P/E is 15.6×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Price / Sales?
Regeneron Pharmaceuticals Inc's Price / Sales is 4.6×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EV / Revenue?
Regeneron Pharmaceuticals Inc's EV / Revenue is 4.7×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EV / EBITDA?
Regeneron Pharmaceuticals Inc's EV / EBITDA is 16.7×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Revenue (TTM)?
Regeneron Pharmaceuticals Inc's Revenue (TTM) is $14.9B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Net Income (TTM)?
Regeneron Pharmaceuticals Inc's Net Income (TTM) is $4.4B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EBITDA?
Regeneron Pharmaceuticals Inc's EBITDA is $4.2B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Diluted EPS (TTM)?
Regeneron Pharmaceuticals Inc's Diluted EPS (TTM) is 42.19, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues:
Net product sales
YoY growth+8.4%-16.4%-18.4%-15.0%
Collaboration revenue
Other revenue
Expenses:
Research and development
Acquired in-process research and development
Selling, general, and administrative
Cost of goods sold
Cost of collaboration and contract manufacturing
Income from operations
% of revenue41.9%52.5%64.7%66.2%
Other income (expense):
Other income (expense), net
Interest expense
Income before income taxes
Income tax expense
Net income
% of revenue47.4%50.4%92.0%85.3%
Net income per share - basic
Net income per share - diluted
Weighted average shares outstanding - basic
Weighted average shares outstanding - diluted
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on debt securities
Gain (loss) on foreign currency translation
Comprehensive income